Novo Nordisk stock is making serious gains after latest GLP-1 trial, which could be even better than Wegovy
Shares of Novo Nordisk surged ~11% on Friday morning after the Wegovy and Ozempic maker announced promising trial results of its experimental weight-loss drug, amycretin.
Patients in the trial lost 9.7% of their body weight after 20 weeks on the lowest dose, and as much as 22% after 36 weeks on the highest dose, according to the company.
While Wegovy only mimics the gut hormone GLP-1 to suppress appetite, amycretin combines GLP-1 with another hunger-regulating hormone, amylin, further enhancing the effect. Patients on the highest dose of amycretin lost up to 13% of their weight over 12 weeks, compared to around 6% for Wegovy users in the same time frame.
The Danish pharma giant’s progress comes amid growing competition from Eli Lilly, which says its obesity drug, Zepbound, offers 47% greater weight loss than Wegovy. Novo’s shares also took a hit last month when disappointing trial results of its next-gen obesity drug, CagriSema, sent its stock tumbling over 20% in a single day.